We are pleased to announce the closing of Longitude Venture Partners IV, L.P.

Learn more
Learn more
×
Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Poseida Therapeutics Receives US FDA Orphan Drug Destination for P-BCMA-101 for the Treatment of Multiple Myeloma

by mparnell | May 13, 2019 | Portfolio News

Molecular Templates, Inc. Reports First Quarter 2019 Financial Results

by mparnell | May 13, 2019 | Portfolio News

Kala Pharmaceuticals Reports First Quarter 2019 Financial Results

by mparnell | May 9, 2019 | Portfolio News

Akebia Therapeutics Reports First Quarter 2019 Financial Results; Announces Full Enrollment of Phase 3 INNO2VATE Studies and Announces Key Executive Appointments

by mparnell | May 9, 2019 | Portfolio News

Sublimity Therapeutics to Present Positive Data for Ulcerative Colitis Drug Candidate

by mparnell | May 8, 2019 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2021 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer